Related Experiment Video
Updated: Feb 25, 2026
09:54
Lentiviral Vector-mediated Gene Therapy of Hepatocytes Ex Vivo for Autologous Transplantation in Swine
Published on: November 4, 2018
8.6K
Gene Therapy in Tyrosinemia: Potential and Pitfalls
Sophie Carter1, Yannick Doyon2
1Centre Hospitalier Universitaire de Québec Research Center and Faculty of Medicine, Centre de recherche du CHU de Québec - Université Laval 2705, boulevard Laurier, T-3-67, Québec, QC, G1V 4G2, Canada.
Advances in Experimental Medicine and Biology
|July 30, 2017
Summary
Gene therapy offers potential treatments for tyrosinemia, a metabolic disorder. This review focuses on viral gene delivery to the liver and CRISPR technology for future therapeutic applications.
Area of Science:
- Medical Genetics
- Molecular Biology
- Pediatric Medicine
Background:
- Tyrosinemia is a rare metabolic disorder requiring effective treatment strategies.
- Gene therapy presents a promising avenue for addressing the underlying genetic causes of tyrosinemia.
- Current therapeutic options for tyrosinemia have limitations, necessitating novel approaches.
Purpose of the Study:
- To provide a comprehensible overview of gene therapy concepts for tyrosinemia.
- To focus on liver-directed gene therapy using viral vectors.
- To discuss the potential and challenges of CRISPR technology in treating metabolic diseases like tyrosinemia.
Main Methods:
- Review of current gene therapy strategies.
- Focus on viral vector-mediated DNA delivery to hepatocytes.
- Exploration of CRISPR-Cas9 gene editing applications.
Main Results:
- Gene therapy, particularly with viral vectors targeting the liver, shows potential for tyrosinemia treatment.
- CRISPR technology offers advanced possibilities for precise genetic correction.
- Understanding potential pitfalls is crucial for successful clinical translation.
Conclusions:
- Gene therapy, especially liver-directed approaches, holds promise for tyrosinemia.
- CRISPR technology represents a significant advancement for metabolic disease gene therapy.
- Further research is needed to overcome challenges and ensure safe application for tyrosinemia.
Related Concept Videos
00:59Gene Therapy
27.8K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.8K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
51
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
51
01:20Inborn Errors of Metabolism
950
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
950
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
36
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
36
00:49What is Genetic Engineering?
80.6K
Overview
80.6K
01:29Drugs Affecting Neurotransmitter Synthesis
2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K